Go to content
Galapagos NV

Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 27 okt 2014 - 07:40
Statutaire naam Galapagos NV
Titel Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK
Bericht Mechelen, Belgium and Cambridge, UK, 27 October 2014: Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, and Calchan Limited, a UK company focused on the development of novel medicines based on calcium ion channel modulators, today announce that they have entered into a research collaboration in the area of osteoarthritis pain. Calchan has been awarded a £2.4 million grant from Innovate UK, the UK's innovation agency, Biomedical Catalyst Early Stage Round 2to discover and develop compounds against a novel target for osteoarthritic pain. Calchan and Galapagos will collaborate in identifying pre-clinical candidates. Subsequently, Calchan and Galapagos may jointly progress the assets further into the clinic. Further financial details remain undisclosed.